klisemfg Chapter 358 The $120 billion acquisition.
Chapter 358 The $120 billion acquisition.
……
"Mr. Chen."
"I have something to tell you."
After Chen Xuan walked out of the laboratory, Luo Shiyun quickly appeared in front of him.
"What's the matter?" Chen Xuan asked puzzledly.
"About Pfizer."
"They have officially acquired Elsilan, and it's a full acquisition." Luo Shiyun knew that Chen Xuan was more concerned about this matter, so she specifically informed him.
"Oh? Has it been acquired?"
"How much did it cost?" Chen Xuan asked with interest.
He didn't expect that such a big thing had happened outside during the time he was in the laboratory.
Pfizer finally acquired Alcilan, but it is unknown how much change this acquisition will bring about.
"$120 billion!"
"Pfizer used this price to acquire all of Elshelan's shares, including all patents for its cancer drug projects."
"Pfizer's market capitalization has risen to $180 billion due to this acquisition, and many financial institutions estimate that its value is likely to reach $200 billion."
Luo Shiyun replied immediately.
Not only did she say it directly, she also told the purchase price and other information.
"$120 billion?"
"Pfizer is making a big move this time."
Hearing Luo Shiyun's words, Chen Xuan couldn't help but be surprised.
120 billion US dollars, which is equivalent to nearly 1000 billion RMB.
Pfizer is willing to pay such a high price for an anti-cancer drug formula that has not yet been approved for market.
Even though this has reached Phase III clinical trials and is performing very well, this price is still a high premium.
After all, even if this anti-cancer drug project can be successfully launched on the market, its efficacy and adverse reactions are actually not as good as his drugs, not to mention its market potential.
This is because they belong to different tracks and there is no competition. Otherwise, there would be no point in listing this drug. The $120 billion acquisition can indeed be considered a high premium.
Of course, Chen Xuan’s medicine is not comparable to ordinary anti-cancer drugs, and it cannot be acquired for a mere $120 billion.
But anyway, in this anti-cancer drug project,
The fact that Pfizer is willing to invest such a large sum of money only shows that its current situation is indeed not very good, otherwise they would not have offered such a high price.
But as to whether this acquisition is worth it, Chen Xuan believes that this is a matter of opinion.
If there are no problems with Elsilan's anti-cancer project and it can be successfully approved for listing and its performance meets expectations, it will not be considered a loss.
At least now that the acquisition has been successful, Pfizer's market value has risen to $180 billion, and it is very likely to reach $200 billion.
Just now, it has increased by hundreds of billions of dollars, almost equivalent to the acquisition price of several Elsirans.
If we look at it from this perspective, the $120 billion acquisition is indeed not a loss, and can even be considered a very high-profit project.
Of course, just because an acquisition increases the market value by tens of billions of dollars does not mean that the project’s returns are that high.
In fact, Chen Xuan believes that the reason for this situation is that
That's because Pfizer's situation is rather special, and its stock price has been sluggish, even falling again and again.
When stock prices remain depressed for a long time, some stimulating good news is needed to bring stock prices back to normal.
Therefore, how much profit this anti-cancer drug project can generate is not the most important thing.
The most important thing is to restore the market's confidence in Pfizer.
Only by restoring confidence can Pfizer's stock price soar and return to its previous market value.
Therefore, Elsilan's anti-cancer drug project only plays a guiding role.
What really determines the market value is Pfizer itself.
If another company were to acquire it, the stock price would not have risen so dramatically.
Rather than being optimistic about this anti-cancer drug project, it is better to be optimistic about the future of Pfizer.
Of course, the launch of the lung cancer drug and its popularity also affected the surge in Pfizer's stock price.
The lung cancer drug has made everyone see the market potential of anti-cancer drugs, and related projects will naturally benefit as well. This also makes Pfizer's acquisition a hot topic.
After winning this anti-cancer drug project, Pfizer's good news became more attractive, which led to a surge in its stock price.
Pfizer probably acquired Elsilan at a high premium just to restore its stock price.
But the premise is that there will be no problems with this anti-cancer drug project. If any hidden dangers are exposed, the greater the rise now, the greater the fall will be in the future.
What’s more serious is that the future decline will be much greater than the current stock price increase. Then it’s not a question of whether it is worth it, but we have to start calculating how much loss this project will cause.
"Mr. Chen, do you think there is any problem with this project?"
"Will this anti-cancer drug project become a new growth point for Pfizer?"
Luo Shiyun asked curiously.
She also wanted to know what Chen Xuan would think of this project?
And will Pfizer be able to regain its former glory with this anti-cancer drug project?
“It’s hard to say, but I’m not optimistic.”
"If anything goes wrong with this project, Pfizer will suffer a lot."
"But no matter what the final result is, Pfizer will definitely focus on promoting this project, which will definitely drive the stock price up even more wildly."
Chen Xuan shook his head and said.
He only knew that there was something fishy going on with the anti-cancer drug project, but because he had too little information, he was unable to find out the real reason.
It is also unknown whether you have a big problem with this project or it is just a minor issue.
However, he is also certain that it is hard to say whether this project will be successful, but it will indeed catalyze a surge in Pfizer's stock price in the near term. The current market value of US$1800 billion has not yet reached its peak, and it will be even crazier in the future.
With Pfizer's many years of experience, they will definitely not miss this opportunity and will definitely publicize this anti-cancer drug project.
Luo Shiyun couldn't help but feel surprised at Chen Xuan's judgment.
The whole world is optimistic about Elsiran's anti-cancer drug project, as can be seen from the skyrocketing stock price.
If the market had not been very optimistic about this project, Pfizer's stock price would not have risen so much.
But he was not optimistic from the beginning to the end, and even now, he still had the same attitude, which surprised her.
But Luo Shiyun still trusts his judgment very much, thinking that he must have his reasons for making such a judgment, and that this project may really fail.
If Pfizer really goes bankrupt because of this project, it will be a great thing for Antai Pharmaceutical Group.
After all, Pfizer's recent operations are more or less targeting the Aetna Group. Whether they like it or not, the two sides have formed a competition, which is inevitable.
In this way, if Pfizer's project fails, it will definitely be welcomed.
……